US 12,030,840 B2
Elafibranor salts
Karine Bertrand, Frelinghien (FR); Alice Roudot, Lomme (FR); and Marie-Jeanne Joissains, Plomelin (FR)
Assigned to GENFIT, Loos (FR)
Appl. No. 17/265,058
Filed by GENFIT, Loos (FR)
PCT Filed Aug. 2, 2019, PCT No. PCT/EP2019/070877
§ 371(c)(1), (2) Date Feb. 1, 2021,
PCT Pub. No. WO2020/025789, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 18306060 (EP), filed on Aug. 3, 2018.
Prior Publication US 2021/0309608 A1, Oct. 7, 2021
Int. Cl. C07C 323/62 (2006.01); A61P 1/16 (2006.01); C07C 319/28 (2006.01)
CPC C07C 323/62 (2013.01) [A61P 1/16 (2018.01); C07C 319/28 (2013.01); C07B 2200/13 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A crystalline salt of elafibranor, selected from the group consisting of a tromethamine salt (salt I), a potassium salt (salt II), and an L-arginine salt (salt IV), of elafibranor.